2 promising small-cap stocks that could be millionaire-makers in 2018

These two shares could help you to generate high returns.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Finding the best stocks at the lowest prices is never easy. However, even though the FTSE All-Share has risen significantly in recent years, there may still be investment opportunities. One sector that could offer high returns is healthcare, with a growing ageing world population providing a potential tailwind.

With that in mind, here are two stocks which could deliver rising share prices in future. As such, they could be worth buying today.

Improving performance

Reporting on Monday was US healthcare market Value Cycle solutions specialist, Craneware (LSE: CRW). The company announced that it has continued to perform strongly in the first half of the year, with its growth strategy successfully executed. Renewals by dollar value have continued at over 100% during the period. It now expects to report an increase in both revenue and adjusted EBITDA (earnings before interest, tax, depreciation and amortisation) of between 15% and 18% for the six months to the end of December 2017.

The company also reported a significant contract win on Monday that’s expected to deliver in excess of $16m of revenue over its initial five-year term. This could prove to be a positive catalyst for a company which has been able to deliver double-digit earnings growth in the last three financial years. This consistently high growth in profitability could show that Craneware is worthy of a premium valuation in the long run.

With the stock currently trading on a price-to-earnings (P/E) ratio of around 38, it seems to be popular among investors. While there may not be scope for a significantly higher rating, the stock’s earnings growth potential remains high. This could propel its share price upwards in the long run.

Upbeat outlook

Also offering growth potential in the healthcare sphere is Alliance Pharma (LSE: APH). The acquirer and licensor of pharmaceutical products has a long track record of delivering growth. It has been able to do so in four of the last five financial years, and this trend looks set to continue over the medium term. In fact, the company is forecast to record a 15% rise in 2018 earnings, which could cause investor sentiment to improve significantly.

Despite a rise in its share price of 38% in the last year, Alliance Pharma trades on a price-to-earnings growth (PEG) ratio of just 1. This suggests it offers a wide margin of safety, which could lead to a higher rating in the long term.

With the company having a stable growth outlook, it may also be seen as a relatively defensive stock. Certainly, it appears to lack a high degree of positive correlation with the wider index and with the economy. This could help investors to diversify at a time when the political risk facing the UK continues to build. As such, now could be the perfect time to buy the stock for the long term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares in Alliance Pharma and Craneware. The Motley Fool UK has recommended Craneware. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

A 9.6% yield but down 14%! Should I consider this FTSE gem for my dividend portfolio?

There are several things to consider when looking for FTSE shares with dividend potential. Here, our writer outlines his evaluation…

Read more »

Young Asian man shopping in a supermarket
Investing Articles

I’d shun Lloyds Banking Group and consider this stock for passive income instead

This company's dividend record knocks spots off Lloyds Banking Group's, and it looks like decent value now with a yield…

Read more »

Investing Articles

Will the 5.6% BT Group dividend yield grow in 2024?

Zaven Boyrazian explores whether BT Group can continue hiking its dividend and if the telecoms giant belongs in his income…

Read more »

Investing Articles

FTSE 100’s near a 52-week high, but this stock’s still dirt cheap!

The FTSE 100's on the rise, but not all stocks have been so fortunate. Here’s one company that got left…

Read more »

Investing Articles

Is this ‘secret weapon’ a multi-billion pound reason to buy Lloyds shares?

Dr James Fox explains how Lloyds shares could rise even higher as the bank's 'strategic hedge' is likely to boost…

Read more »

Smiling senior white man talking through telephone while using laptop at desk.
Investing Articles

3 of the best penny stocks for growth, dividends, and value!

Looking for top penny stocks to buy? Royston Wild believes these UK small-cap shares could prove lucrative investments in the…

Read more »

Investing Articles

How I’d aim to turn an empty ISA into £275k by purchasing cheap shares this summer

Harvey Jones is taking advantage of the summer stock market lull to buy cheap shares and build a high and…

Read more »

Investing Articles

What’s the minimum I need to invest every month to earn a meaningful passive income?

When looking to secure a stream of passive income it's important to be realistic. Our writer investigates a strategy to…

Read more »